Olipudase alfa

XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Hypersensitivity Reactions Including Anaphylaxis
Infusion-Associated Reactions (IARs)
Elevated Transaminase Levels

Who should not take it

None.

Storing it

Storage and Handling

Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.

For storage of reconstituted and diluted solution.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Olipudase alfa; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/olipudase-alfa
APA 7th: sofidex. (2026, August 3). Olipudase alfa. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/olipudase-alfa
AMA 11th: Olipudase alfa. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/olipudase-alfa

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.